Neurofibromatosis: part 2--clinical management

Arq Neuropsiquiatr. 2015 Jun;73(6):531-43. doi: 10.1590/0004-282X20150042.


Part 1 of this guideline addressed the differential diagnosis of the neurofibromatoses (NF): neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SCH). NF shares some features such as the genetic origin of the neural tumors and cutaneous manifestations, and affects nearly 80 thousand Brazilians. Increasing scientific knowledge on NF has allowed better clinical management and reduced rate of complications and morbidity, resulting in higher quality of life for NF patients. Most medical doctors are able to perform NF diagnosis, but the wide range of clinical manifestations and the inability to predict the onset or severity of new features, consequences, or complications make NF management a real clinical challenge, requiring the support of different specialists for proper treatment and genetic counseling, especially in NF2 and SCH. The present text suggests guidelines for the clinical management of NF, with emphasis on NF1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease Management
  • Humans
  • Neurilemmoma / complications
  • Neurilemmoma / pathology
  • Neurilemmoma / therapy*
  • Neurofibromatoses / complications
  • Neurofibromatoses / pathology
  • Neurofibromatoses / therapy*
  • Neurofibromatosis 1 / complications
  • Neurofibromatosis 1 / pathology
  • Neurofibromatosis 1 / therapy*
  • Neurofibromatosis 2 / complications
  • Neurofibromatosis 2 / pathology
  • Neurofibromatosis 2 / therapy*
  • Optic Nerve Glioma / pathology
  • Optic Nerve Glioma / therapy
  • Risk Factors
  • Skin Neoplasms / complications
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*

Supplementary concepts

  • Schwannomatosis